Neuroendocrine Tumor G2 — Trials

Neuroendocrine Tumor G2 — Trials · CancerIndex

Clinical trials

Registered studies

20 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

clinicaltrialsPublishedShowing 1–20 of 20 studies · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT05773274	Comparing Retreatment of 177Lu-DOTATATE PRRT Versus the Usual Treatment in Patients With Metastatic Unresectable Gastroenteropancreatic Neuroendocrine Tumors, NET RETREAT Trial	recruiting	Phase 2	100	National Cancer Institute (NCI)NIH	2	Sep 24, 2026	clinicaltrials
NCT03375320	Testing Cabozantinib in Patients With Advanced Pancreatic Neuroendocrine and Carcinoid Tumors	active not recruiting	Phase 3	298	National Cancer Institute (NCI)NIH	1	Sep 22, 2026	clinicaltrials
NCT04665739	Testing Lutetium Lu 177 Dotatate in Patients With Somatostatin Receptor Positive Advanced Bronchial Neuroendocrine Tumors	recruiting	Phase 2	70	National Cancer Institute (NCI)NIH	1	Sep 17, 2026	clinicaltrials
NCT00569127

Data updated 4 days agoSource updated Sep 24, 2026source: clinicaltrials